Health Care & Life Sciences » Pharmaceuticals | Hisamitsu Pharmaceutical Co. Inc.

Hisamitsu Pharmaceutical Co. Inc. | Mutual Funds

Mutual Funds that own Hisamitsu Pharmaceutical Co. Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total International Stock Index Fund
1,032,334
1.09%
24,800
0.02%
07/31/2018
Nomura Asset TOPIX ETF Fund (1306)
933,100
0.98%
14,800
0.1%
07/31/2018
Government Pension Fund - Global (The)
694,099
0.73%
-268,501
0.01%
12/31/2017
Daiwa Asset TOPIX Listed ETF (1305)
458,000
0.48%
12,400
0.1%
07/31/2018
Nikko Asset Listed Index TOPIX ETF (1308)
420,200
0.44%
0
0.1%
08/20/2018
Vanguard Developed Markets Index Fund
406,293
0.43%
-212
0.03%
07/31/2018
iShares MSCI EAFE ETF
337,700
0.36%
0
0.04%
09/06/2018
iShares MSCI Japan ETF
254,200
0.27%
0
0.11%
09/06/2018
iShares Core MSCI EAFE ETF
219,200
0.23%
0
0.03%
09/06/2018
Canada Pension Plan
182,000
0.19%
-129,000
0%
03/31/2018

About Hisamitsu Pharmaceutical Co.

View Profile
Address
408 Tashiro Daikan-machi
Tosu Saga 841
Japan
Employees -
Website http://www.hisamitsu.co.jp
Updated 07/08/2019
Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, Lifecella, and Keplat brands. It also provides ethical pharmaceuticals, over the counter drugs, medical devices, health supplements, and topical analgesic products.